Clinical trials: Adverse Reaction
Adverse Drug Events
Reducing Adverse Drug Events in the Nursing Home
Medications are the single most common form of treatment in the long-term care setting, and often represent the most efficacious (and cost-effective) therapeutic modality used in this clinical setting.
- Trial name
- NCT00606606
- Testing
- Clinical Decision Support
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Adverse Effect of Drugs and Medicaments in Therapeutic Use, Adverse Effects in the Therapeutic Use of Anaesthetics
The Effect of Opioid Free Anesthesia in Bariatric Surgeries
This is a prospective randomized controlled study that will be carried out on morbid obese patients admitted to Tanta University hospitals for laparoscopic bariatric surgeries.
- Trial name
- Opioidfree (NCT04048200)
- Testing
- Fentanyl, Dexmedetomidine Ketamine
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Biotherapy, Chronic Inflammatory Disease
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a…
- Conditions
- Biotherapy, Chronic Inflammatory Disease, Allergic Skin Reaction, Pediatric Disorder
- Trial name
- MDEBMIC (NCT04327752)
- Testing
- dermatological consultation
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Oncolytic Virus, Diffuse Intrinsic Pontine Glioma
Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma
This is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in…
- Conditions
- Oncolytic Virus, Diffuse Intrinsic Pontine Glioma, Adverse Drug Event
- Trial name
- NCT05717699
- Testing
- Ad-TD-nsIL12
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Capital Medical University
Adverse Effect
ED90 of Norepinephrine and Phenylephrine Infusions Under Intensive Treatment
The objective of this study is to investigate the ED90 of norepinephrine and phenylephrine infusions for preventing postspinal anesthesia hypotension under intensive treatment during cesarean section
- Trial name
- NCT06158048
- Testing
- Norepinephrine, Phenylephrine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- General Hospital of Ningxia Medical University
Medication-Induced Dyskinesia
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA…
- Trial name
- NCT05148884
- Testing
- NLX-112
- Where
- 5 sites in Sweden
- Volunteers
- 27 people
- Sponsor
- Neurolixis SAS
Statin Adverse Reaction
Exercise Intensity and Muscle Recovery in Statin Users
This study aims to investigate how different types and intensities of exercise affect muscle recovery in individuals taking statin medications compared to healthy controls.
- Trial name
- STN-EX (NCT07563452)
- Testing
- Dose-Escalation Exercise Protocol
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Raffaele Mazzolari
Graft Versus Host Disease, Hematologic Malignancy
Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
This is a two arm open label phase III clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they meet the standard criteria defined in the…
- Conditions
- Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction
- Trial name
- CY25 (NCT05158608)
- Testing
- Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics
Pharmaceutical Services, Medication Errors
Effect and Associated Factors of the Clinical Pharmacy Model in the Incidence of Medical Errors
Medication errors are considered by WHO to be a subject that requires attention at all levels of care, in order to reduce the serious and preventable damage related to medication.
- Conditions
- Pharmaceutical Services, Medication Errors, Drug-Related Side Effects and Adverse Reactions, Outcome Assessment (Health Care)
- Trial name
- EACPharModel (NCT03338725)
- Testing
- Clinical pharmacy model
- Where
- Colombia
- Volunteers
- 720 people
- Sponsor
- Universidad de Antioquia
Patient Readmission, Adverse Drug Event
Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization
Among older VA patients who have Medicare coverage, 43% use both VA and non-VA (Medicare-covered) services. VA and non-VA providers are often uninformed about encounters, treatments and test results provided in the other system.
- Conditions
- Patient Readmission, Adverse Drug Event, Cost
- Trial name
- NCT02689076
- Testing
- HIE Notification, Care transitions intervention
- Where
- 2 sites in United States
- Volunteers
- 796 people
- Sponsor
- VA Office of Research and Development
Drug-Related Side Effects and Adverse Reactions
Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
It concerns an investigation aiming to investigate genetic biological(s) marker(s) which allow to identify individuals who have risk of serious adverse events to the yellow fever vaccine.
- Trial name
- NCT03938597
- Where
- Brazil
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Vomiting, Cisplatin Adverse Reaction
Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy
Gabapentin is an antiepileptic drug. Its antiemetic effect is demonstrated after laparoscopic surgery, but it is not yet known whether gabapentin is effective in preventing chemotherapy induced emesis.
- Trial name
- NCT01052844
- Testing
- Gabapentin
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Faculdade de Medicina do ABC
Prostate Cancer
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
The percentage of malignant prostate tumors detected very early is constantly increasing and the number of well differentiated tumors, with small volume and low risk of progression increases.
- Trial name
- HIFUSA (NCT03531099)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 108 people
- Sponsor
- Hospices Civils de Lyon
COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction
COVID-19 Vaccination Detoxification in LDL-C
The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810.
- Conditions
- COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism, COVID-19 Post-Intensive Care Syndrome
- Trial name
- NCT05839236
- Testing
- Atorvastatin Calcium Tablets
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Yang I. Pachankis
Adverse Effects, Dental Restoration, Permanent
Health Effects From Removal of Amalgam Restorations in Patients With Symptoms Allegedly Related to Dental Amalgam
The aim of the project is to study changes in symptom load after removal of all dental amalgam restorations in patients with symptoms allegedly related to amalgam.
- Trial name
- NCT00346944
- Testing
- Removal of dental amalgam restorations
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- University of Bergen
Effect of Drug, Toxicity, Drug
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse…
- Trial name
- AIEO (NCT04824352)
- Testing
- apatinib
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University People's Hospital
Pesticide Adverse Reaction
Immunological Indices and Infections Among Pesticide Applicators in Sohag Governorate
The human body gets exposure to pesticides either directly or indirectly. By using pesticides on crops, humans come in direct contact with them and they affect the heaith Immune system is the first defense line against pathogenic…
- Trial name
- NCT05828563
- Testing
- Blood sample test
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.